Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interfant-21: International collaborative protocol for infants with KMT2A-rearranged ALL or MPAL
jRCTs051230126Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Sep 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Open-label, single-arm trial of blinatumomab in acute lymphoblastic leukemia (ALL) and mixed phenotype acute leukemia (MPAL), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Event-free survival (EFS). Started Sep 2024; status: recruiting.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on jRCTs051230126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051230126.